Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Chronic kidney disease
•
Nephrology
Would you recommend avoiding intravesical (bladder) tobramycin administration in a patient with advanced chronic kidney disease?
Related Questions
How do you approach managing patients with diabetic kidney disease and proteinuria who develop hypoglycemia after initiation of a SGLT2 inhibitor?
What is your preferred iron loading strategy for patients with anemia of chronic kidney disease?
Would you avoid using cephalosporins in a patient with a history of cephalosporin neurotoxicity in the setting of CKD?
Do you recommend avoiding SGLT2i use for patients with proteinuria from diabetic kidney disease if they have urinary retention requiring catheterization?
How do you clinically distinguish between pericardial effusion from volume overload versus uremic pericarditis in advanced CKD?
Is it safe to use acarbose in patients with advanced chronic kidney disease?
How do you approach the management of ADPKD in pregnancy, considering the need to stop tolvaptan therapy?
Under what circumstances would you consider a kidney biopsy in an HIV patient with subnephrotic range proteinuria, microscopic hematuria, and stable renal function who has been on a tenofovir-based regimen?
What is your approach to managing hyperkalemia in pregnant patients with chronic kidney disease?
Do you obtain a urinalysis for glucose testing for your patients on SGLT2 inhibitors to assess for medication adherence?
